期刊
EMERGING MICROBES & INFECTIONS
卷 11, 期 1, 页码 1518-1523出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2022.2078230
关键词
Omicron variant; COVID-19; VV116; cohort study; viral load
资金
- Shanghai Science and Technology Committee [22YJ1900102, 22YJ1900100]
- Shanghai Municipal Science and Technology Major Project, Shanghai Science and Technology Committee [21NL2600100, 20dz2260100, 20dz2210400]
- Key Discipline Construction Plan from Shanghai Municipal Health Commission [GWV-10.1-XK01, GWV-3.1, GWV2]
- Lingang Laboratory [LG-YJ-202204-02]
- clinical key specialty project on Shanghai infectious diseases [shslczdzk01102]
VV116 is a safe and effective oral antiviral drug that shows better performance in the early onset of omicron infection.
Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. We conducted an open, prospective cohort study to evaluate its safety and effectiveness in Chinese participants infected with the omicron variant from March 8th, 2022 to March 24th, 2022. 136 hospitalized nonsevere patients confirmed with COVID-19 were enrolled including 60 patients who received VV116 (300 mg, BIDx5 days) in the treatment group and 76 patients who didn't receive VV116 in the control group besides standard treatment. Viral load shedding time and adverse events were collected during the follow-up. There was no significant difference in baseline characteristics between the VV116 group and the control group, except for a higher symptom prevalence in the control group (P = 0.021). The median time from the first positive test to the first VV116 administration was 5 (range: 2-10) days. Participants who received VV116 within 5 days since the first positive test had a shorter viral shedding time than the control group (8.56 vs 11.13 days), and cox regression analysis showed adjusted HR of 2.37 [95%CI 1.50-3.75], P < 0.001. In symptomatic subgroup, VV116 group had a shorter viral shedding time than the control group (P = 0.016). A total of 9 adverse events with no serious adverse events were reported in the VV116 group, all of them were resolved without intervention. VV116 is a safe, effective oral antiviral drug, which shows a better performance within the early onset of omicron infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据